Truist raised the firm’s price target on Edgewise Therapeutics (EWTX) to $50 from $33 and keeps a Buy rating on the shares. The firm has greater conviction in the potential for share upside based on due diligence, management commentary, positive KOL feedback, and expectations for data readouts in bone mineral density and hypertrophic cardiomyopathy, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- Edgewise Therapeutics initiated with an Outperform at Evercore ISI
- Edgewise Therapeutics Reports Q3 Progress in Muscle Disease Trials
- Edgewise Therapeutics reports Q3 EPS (36c), consensus (37c)
- Edgewise Therapeutics call volume above normal and directionally bullish
- Edgewise Therapeutics price target raised to $51 from $48 at Piper Sandler